<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lonial, S.</style></author><author><style face="normal" font="default" size="100%">Dimopoulos, M.</style></author><author><style face="normal" font="default" size="100%">Palumbo, A.</style></author><author><style face="normal" font="default" size="100%">White, D.</style></author><author><style face="normal" font="default" size="100%">Grosicki, S.</style></author><author><style face="normal" font="default" size="100%">Spicka, I.</style></author><author><style face="normal" font="default" size="100%">Walter-Croneck, A.</style></author><author><style face="normal" font="default" size="100%">Moreau, P.</style></author><author><style face="normal" font="default" size="100%">Mateos, M.-V.</style></author><author><style face="normal" font="default" size="100%">Magen, H.</style></author><author><style face="normal" font="default" size="100%">Belch, A.</style></author><author><style face="normal" font="default" size="100%">Reece, D.</style></author><author><style face="normal" font="default" size="100%">Beksac, M.</style></author><author><style face="normal" font="default" size="100%">Spencer, A.</style></author><author><style face="normal" font="default" size="100%">Oakervee, H.</style></author><author><style face="normal" font="default" size="100%">Orlowski, R.Z.</style></author><author><style face="normal" font="default" size="100%">Taniwaki, M.</style></author><author><style face="normal" font="default" size="100%">Röllig, C.</style></author><author><style face="normal" font="default" size="100%">Einsele, H.</style></author><author><style face="normal" font="default" size="100%">Wu, K.L.</style></author><author><style face="normal" font="default" size="100%">Singhal, A.</style></author><author><style face="normal" font="default" size="100%">San-Miguel, J.</style></author><author><style face="normal" font="default" size="100%">Matsumoto, M.</style></author><author><style face="normal" font="default" size="100%">Katz, J.</style></author><author><style face="normal" font="default" size="100%">Bleickardt, E.</style></author><author><style face="normal" font="default" size="100%">Poulart, V.</style></author><author><style face="normal" font="default" size="100%">Anderson, K.C.</style></author><author><style face="normal" font="default" size="100%">Richardson, P.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Elotuzumab therapy for relapsed or refractory multiple myeloma</style></title><secondary-title><style face="normal" font="default" size="100%">New England Journal of Medicine</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2015</style></date></pub-dates></dates><urls><web-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84933569079&amp;doi=10.1056%2fNEJMoa1505654&amp;partnerID=40&amp;md5=ebfafb9d968ec8e4d796bb4ac87de97e</style></url></web-urls></urls><volume><style face="normal" font="default" size="100%">373</style></volume><pages><style face="normal" font="default" size="100%">621 - 631</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">Background: Elotuzumab, an immunostimulatory monoclonal antibody targeting signaling lymphocytic activation molecule F7 (SLAMF7), showed activity in combination with lenalidomide and dexamethasone in a phase 1b-2 study in patients with relapsed or refractory multiple myeloma. Methods: In this phase 3 study, we randomly assigned patients to receive either elotuzumab plus lenalidomide and dexamethasone (elotuzumab group) or lenalidomide and dexamethasone alone (control group). Coprimary end points were progression-free survival and the overall response rate. Final results for the coprimary end points are reported on the basis of a planned interim analysis of progression-free survival. Results: Overall, 321 patients were assigned to the elotuzumab group and 325 to the control group. After a median follow-up of 24.5 months, the rate of progression-free survival at 1 year in the elotuzumab group was 68%, as compared with 57% in the control group; at 2 years, the rates were 41% and 27%, respectively. Median progression-free survival in the elotuzumab group was 19.4 months, versus 14.9 months in the control group (hazard ratio for progression or death in the elotuzumab group, 0.70; 95% confidence interval, 0.57 to 0.85; P&lt;0.001). The overall response rate in the elotuzumab group was 79%, versus 66% in the control group (P&lt;0.001). Common grade 3 or 4 adverse events in the two groups were lymphocytopenia, neutropenia, fatigue, and pneumonia. Infusion reactions occurred in 33 patients (10%) in the elotuzumab group and were grade 1 or 2 in 29 patients. Conclusions: Patients with relapsed or refractory multiple myeloma who received a combination of elotuzumab, lenalidomide, and dexamethasone had a significant relative reduction of 30% in the risk of disease progression or death. Copyright © 2015 Massachusetts Medical Society. All rights reserved.</style></abstract><issue><style face="normal" font="default" size="100%">7</style></issue><notes><style face="normal" font="default" size="100%">Cited By :160Export Date: 21 February 2017</style></notes></record></records></xml>